Fulcrum Therapeutics (FULC) PT Lowered to $14 at Oppenheimer

May 13, 2024 4:22 PM

Oppenheimer analyst Matthew Biegler lowered the price target on Fulcrum Therapeutics (NASDAQ: FULC) to $14.00 (from $16.00) while maintaining a Outperform rating.

No results found